SYTL2 Human Pre-designed siRNA Set A contains three designed siRNAs for SYTL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SYTL3 Human Pre-designed siRNA Set A contains three designed siRNAs for SYTL3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SYTL4 Human Pre-designed siRNA Set A contains three designed siRNAs for SYTL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SYTL5 Human Pre-designed siRNA Set A contains three designed siRNAs for SYTL5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SYVN1 Human Pre-designed siRNA Set A contains three designed siRNAs for SYVN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SZRD1 Human Pre-designed siRNA Set A contains three designed siRNAs for SZRD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SZT2 Human Pre-designed siRNA Set A contains three designed siRNAs for SZT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

T-0509 ((-)-T-0509) is a selective full agonist of the β1 receptor. T-0509 activates the cAMP signaling pathway through the β1 receptor and enhances myocardial contractility[1].

T-1-PMPA is a potent EGFR inhibitor with apoptotic properties. T-1-PMPA effectively inhibits EGFRWT and EGFR790m, with IC50 values of 86 nM and 561.73 nM, respectively[1].

T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6. T-581 can be used in research on tauopathy[1].

T-705RMP (ammonium) is the ammonium form of T-705RMP. T-705RMP (ammonium)’s the inhibition of IMP dehydrogenase (IMPDH) activity is weak [1].

T-705RMP (ammonium) is the ammonium form of T-705RMP. T-705RMP (ammonium)’s the inhibition of IMP dehydrogenase (IMPDH) activity is weak [1].

T-705RMP (ammonium) is the ammonium form of T-705RMP. T-705RMP (ammonium)’s the inhibition of IMP dehydrogenase (IMPDH) activity is weak [1].

T-705RMP (ammonium) is the ammonium form of T-705RMP. T-705RMP (ammonium)’s the inhibition of IMP dehydrogenase (IMPDH) activity is weak [1].

T-705RMP (ammonium) is the ammonium form of T-705RMP. T-705RMP (ammonium)’s the inhibition of IMP dehydrogenase (IMPDH) activity is weak [1].

T-Cadinol is a sesquiterpene isolated from C. sylvestris that exhibits anti-Trypanosoma cruzi activity, with IC50 values of 18.2 μM and 15.8 μM against trypomastigote and amastigote forms, respectively. T-Cadinol can induce mitochondrial damage in parasites, leading to membrane hyperpolarization and decreased levels of reactive oxygen species. T-Cadinol can be used for the research of Chagas […]

T0070907-d4 is the deuterium labeled T0070907 (HY-13202). T0070907 is a potent PPARγ antagonist[1].

T0070907-d4 is the deuterium labeled T0070907 (HY-13202). T0070907 is a potent PPARγ antagonist[1].

T0070907-d4 is the deuterium labeled T0070907 (HY-13202). T0070907 is a potent PPARγ antagonist[1].

T100-Mut is a cell-permeable peptide whose N-terminus is conjugated with a myristoylated group, allowing it to penetrate and localize to the intracellular side of the plasma membrane, thus mimicking the topology of Tmem100-3Q. T100-Mut can alleviate TRPA1-mediated pain[1].

T3SS-IN-4 (Compound Z-8) is a T3SS inhibitor that can inhibit the expression of Xanthomonas oryzae pv oryzae (Xoo) T3SS-related genes without affecting bacterial growth. T3SS-IN-4 can effectively reduce the hypersensitive response (HR) induced by Xoo in tobacco and lower the pathogenicity of Xoo in rice[1].

T3SS-IN-5 (Compound F9) is a specific inhibitor of the type III secretion system (T3SS). T3SS-IN-5 reduces bacterial pathogenicity without affecting bacterial viability by inhibiting the expression of genes associated with T3SS[1].

T4-BSA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of T4 (HY-18341) and BSA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

TAAR1 agonist 1 (compound 6E) is a potent TAAR1 agonist with a potent TAAR1-Gs/Gq dual-pathway activation property. TAAR1 agonist 1 significantly alleviates MK-801-induced schizophrenia-like cognitive phenotypes[1].

TAAR1 agonist 1 hydrochloride (6e·HCl) is a novel G-protein-coupled receptor TAAR1 agonist. TAAR1 agonist 1 hydrochloride is used in the study of schizophrenia[1].

TAAR1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAAR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAAR2 Human Pre-designed siRNA Set A contains three designed siRNAs for TAAR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAAR5 Human Pre-designed siRNA Set A contains three designed siRNAs for TAAR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAB1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAB2 Human Pre-designed siRNA Set A contains three designed siRNAs for TAB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAB3 Human Pre-designed siRNA Set A contains three designed siRNAs for TAB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tabimorelin (NN703) is an orally active growth hormone (GH) secretagogue. Tabimorelin is also a potent inhibitor of CYP3A4 activity[1].

TABS (N-Tris(hydroxymethyl)methyl-4-aminobutanesulfonic acid) is a zwitterionic chemical buffering agent, is broadly applied in cell culture[1].

TAC1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAC3 Human Pre-designed siRNA Set A contains three designed siRNAs for TAC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAC4 Human Pre-designed siRNA Set A contains three designed siRNAs for TAC4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TACC1 Human Pre-designed siRNA Set A contains three designed siRNAs for TACC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TACC2 Human Pre-designed siRNA Set A contains three designed siRNAs for TACC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TACC3 Human Pre-designed siRNA Set A contains three designed siRNAs for TACC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TACO1 Human Pre-designed siRNA Set A contains three designed siRNAs for TACO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.